Загрузка...
Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity
BACKGROUND: Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We investigated whether crizotinib could influence heart rate (HR)...
Сохранить в:
| Опубликовано в: : | Cardiooncology |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5310672/ https://ncbi.nlm.nih.gov/pubmed/28217366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-017-0020-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|